Heteroaryl[4,3-C]pyrimidine-5-amine Derivatives for Selective A2a Antagonism
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current A2a receptor antagonists face issues such as low solubility, photosensitivity, low activity, low selectivity, and low bioavailability, leading to adverse effects like anxiety and increased risk of ischemic heart disease when blocking A1 and A3 receptors, which are involved in regulating cellular responses to hypoxia and ischemia.
Innovation Solution
Development of a novel heteroaryl[4,3-c]pyrimidine-5-amine derivative with a potent inhibition activity as an A2a receptor antagonist, which has high selectivity, low brain penetration, and reduced side effects by minimizing interaction with A1 and A3 receptors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current A2a receptor antagonists are used to treat neurodegenerative diseases, then therapeutic efficacy is achieved, but solubility is low and photosensitivity occurs
Solution Approach 1:
The patent modifies the chemical structure parameters of A2a receptor antagonists by introducing heteroaryl[4,3-c]pyrimidine-5-amine derivatives with specific substituent groups (R1-R6), thereby changing the physicochemical properties to improve solubility while maintaining therapeutic efficacy against neurodegenerative diseases
Solution Approach 2:
The invention creates composite molecular structures by combining heteroaryl groups with pyrimidine-5-amine core structures, forming new compounds that exhibit improved solubility and reduced photosensitivity while retaining A2a receptor antagonistic activity
2Reliability
If A2a receptor antagonists are used to treat neurodegenerative diseases, then therapeutic effect is achieved, but selectivity is low causing adverse effects
Solution Approach 1:
The patent introduces specific substituent groups (R1-R6) at different positions of the pyrimidine core structure, creating local structural variations that enhance selective binding to A2a receptors while minimizing interactions with A1 and A3 receptors, thereby reducing adverse effects such as anxiety and ischemic heart disease risk
Solution Approach 2:
The invention designs compounds that replicate the desired selective binding properties by creating multiple analogues with systematically varied substituents, allowing identification of structures with optimal A2a selectivity and reduced off-target effects
3Reliability
If A2a receptor antagonists are used for treatment, then neuroprotective effects are achieved, but bioavailability is low
Solution Approach 1:
The patent optimizes bioavailability by modifying molecular parameters including adding solubilizing groups (such as hydroxyl, alkoxy, or heteroaryl substituents) and adjusting molecular weight and lipophilicity through systematic variation of R1-R6 groups, thereby enhancing absorption and distribution while maintaining neuroprotective efficacy
Data Source
AI summary
A heteroaryl[4,3-c]pyrimidin-5-amine derivative, a preparation method therefor, and medical uses thereof are provided. Specifically, a heteroaryl[4,3-c]pyrimidin-5-amine derivative of formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, and uses thereof as therapeutic agents are provided. In particular, the provided compounds can be used as A2a receptor antagonists and for treatment of conditions or symptoms that are ameliorated by inhibiting the A2a receptor. The various substituent groups in the formula (I) have the meanings as described in the specification.